IRLAB Therapeutics (OMX: IRLAB-A) misses primary endpoint with pirepemat
IRLAB Therapeutics has announced top-line results from the Phase IIb REACT-PD study evaluating its second most clinically advanced asset, pirepemat, as a potential treatment for falls related to Pa...
Publicado el: 2025-03-05 15:34:00
Autor: finanznachrichten, Fuente: finanznachrichten
Compartir: 
